182 results
Page 5 of 10
8-K
EX-10.3
us23xzd9bg x7mr
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
S-8
m85lytelexbkee8
27 Mar 20
Registration of securities for employees
8:38am
S-8
EX-23.1
kvnukiv ugrmioj
27 Mar 20
Registration of securities for employees
8:38am
8-K
EX-99.2
6dizyip90r8d
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.1
ma3wfexjlxkib3bx4
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
612cq
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
fra2f7
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
iatzob3z
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-10.4
6phe01zf
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.3
i1uzq55xzl84hh
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.1
apf2bxd brtj2cuj1v
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
bpm1cc0
2 Dec 19
Other Events
5:18pm
8-K
EX-1.1
abi905qr
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
424B5
vn19t5y4r1a h8j
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
rcc86l85 o67
26 Nov 19
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
gnunzi3hb74cajzn
20 Nov 19
Other Events
7:05am